Linneaus Bioscience Inc is a biotech company focused on the dicovery, development, and commercialization of technologies in drug discovery. The company has developed an antibiotic discovery research platform, Bacterial Cytological Profiling (BCP), which uses quantitative cell biology methods to study how different conditions or drugs affect the overall cytological characteristics of microbial cells. Currently focused on E. coli, A. baumannii, P. aeruginosa, and K. pneumoniae, their BCP platform identifies novel chemical scaffolds to hit new targets in drug resistant gram negative pathogens. The company also offers services including the screening of libraries to identify novel antibiotics, determining the mode of action for newly discovered antimicrobial compounds, determining how compounds enter bacterial cells, and others.
